CRISPR Diagnostics in 2026

How DETECTR, SHERLOCK, and next-gen CRISPR platforms earned their place in clinical workflows and why the enzymes powering them need to be ultrapure.

By 2026, CRISPR-based diagnostics have moved decisively from academic proof-of-concept into clinical deployment. Regulatory clearances are accumulating, commercial partnerships are maturing, and a growing field of companies are bringing CRISPR detection to infectious disease labs, oncology centers, and point-of-care settings. What has made or broken those efforts, more than any single assay design choice, is the quality of the enzymes at the core of the reaction.

The Major Platforms: Where They Stand in 2026

DETECTR (Cas12-based DNA Detection)

Mammoth Biosciences' DETECTR® platform was among the earliest CRISPR diagnostics to reach the market during COVID: the FDA issued an Emergency Use Authorization (EUA) on August 31, 2020 for the SARS-CoV-2 DETECTR Reagent Kit (and later an EUA for DETECTR BOOST in January 2022). The underlying detection concept relies on Cas12-family “collateral cleavage” (activated after target recognition) as the signal-generation mechanism used in DETECTR-style assays.

Since then, Mammoth has publicly emphasized a stronger push into gene-editing therapeutics, including a major Regeneron collaboration announced April 25, 2024, which included $100M in upfront cash/equity investment and potential downstream milestones.

SHERLOCK and INSPECTR (now part of OraSure Technologies)

Sherlock Biosciences developed two main diagnostic technology tracks before being acquired by OraSure Technologies (NASDAQ: OSUR), a deal OraSure announced on December 19, 2024: SHERLOCK, a CRISPR diagnostic approach that leverages Cas13 target recognition to trigger collateral cleavage of RNA reporters and that received an FDA EUA in May 2020 for SARS-CoV-2 testing, and INSPECTR, a distinct synthetic-biology, cell-free detection concept described as using ligation-generated templates to drive cell-free reporter protein expression with readouts that can include lateral flow and are discussed in the context of ambient-temperature workflows; in February 2023, Sherlock also acquired Sense Biodetection, noting that Sense’s Veros™ COVID-19 rapid molecular test had achieved a CE Mark in March 2022; following the OraSure acquisition, OraSure highlighted Sherlock’s molecular CT/NG self-test as a core pipeline program—stating it was in clinical studies with FDA submission targeted for end of 2025—and later reported that the CT/NG test was submitted to FDA in early January 2026.

VedaBio and the Amplification-Free Frontier

VedaBio (San Diego) is a newer CRISPR diagnostics company with roots at the University of Illinois Urbana–Champaign (it previously operated as LabSimply) and is developing its CRISPR Cascade™ concept for amplification-free nucleic acid detection with a positive-feedback design aimed at results in ~10 minutes. In September 2025, VedaBio announced a non-exclusive IP license from Mammoth Biosciences and, later that month, a strategic agreement with Siemens Healthineers alongside a Series A extension totaling up to $25M. Because amplification-free detection relies on enzyme behavior to produce signal (instead of target amplification), it typically demands especially strong enzyme purity and lot consistency to minimize background and preserve signal-to-noise.

One additional player worth watching as the ecosystem matures:

CrisprBits is a Bengaluru-based CRISPR diagnostics company (founded 2020, per company/press coverage) that developed OmiCrisp, a Cas12a-based SARS-CoV-2 test designed to distinguish Omicron vs non-Omicron lineages and that has been used for weekly wastewater surveillance across 14 Bengaluru localities (reported in Feb 2024 and consistent with a 14-locality sampling set described in a related preprint). In August 2023, CrisprBits signed an MoU/collaboration with Molbio Diagnostics to integrate CRISPR chemistry into Molbio’s established point-of-care platform and leverage Molbio’s manufacturing and commercial network for distribution. Beyond respiratory surveillance, CrisprBits has expanded into antimicrobial resistance (AMR) with PathCrisp, a LAMP-coupled Cas12a assay for detecting the NDM carbapenem-resistance gene, published in Scientific Reports (2025): the paper reports results in ~2 hours at constant temperature, compatibility with crude heat extraction from culture, and 100% concordance with PCR–Sanger sequencing in their evaluated sample set (including 49 CRE clinical samples noted in the study’s comparison).

Regulatory Milestones at a Glance

Why Enzyme Purity Is the Non-Negotiable Variable

The collateral cleavage activity that makes CRISPR diagnostics work is also what makes enzyme quality so unforgiving. Once a Cas12 or Cas13 enzyme is activated by its target, it cleaves nearby nucleic acids indiscriminately generating the amplified fluorescent or lateral-flow signal that enables attomolar detection. Contaminating nucleases in a poorly purified Cas preparation will do the same thing without any target present, raising the background signal and obliterating the assay's limit of detection. This is why the procurement standard for CRISPR enzyme reagents in a diagnostic context is categorically different from gene editing procurement.

The Road Ahead for CRISPR-based Diagnostics

Several trends are likely to shape CRISPR diagnostics through 2027 and beyond. Oncology liquid biopsy is one of the most plausible sources of the next major regulatory activity as larger clinical validation datasets accumulate and companies translate high-performing laboratory workflows into more standardized offerings. In parallel, point-of-care expansion should accelerate as platforms improve ambient-temperature stability and as cartridge-based formats become more cost-competitive—shifting CRISPR from “high-promise chemistry” into repeatable, scalable product workflows.

What’s especially interesting is that the next generation of CRISPR diagnostics may not look like the first. Teams like GRIP Molecular Technologies are pushing new architectures, describing a CRISPR protease engine designed for room-temperature operation and no nucleic-acid pre-amplification, with flexibility across readout formats, aiming to reduce workflow complexity without losing specificity. In the same spirit, VedaBio positions its CRISPR Cascade™ around amplification-free detection and has attracted strategic partnering attention, signaling serious interest in formats that simplify the path to decentralized testing.

As these approaches mature, a quieter (but equally consequential) shift is emerging: the formalization of diagnostics-grade enzyme specifications. As regulatory guidance and industry standards evolve, today’s “best-practice” procurement requirements around purity, consistency, and traceability can become tomorrow’s expected minimums. Developers building on platforms like DETECTR, CRISPR Cascade™, or other Cas-based formats will be better positioned if they establish auditable, reliable supply relationships for ultra-pure enzymes early, before those expectations harden into the rules of the road.

Browse the TriAltus Enzyme Catalog →

TriAltus: CRISPR Enzymes - Built for Diagnostic Demands

TriAltus produces ultra-pure Cas enzymes designed for the realities of diagnostic development, where lot consistency, traceable QC, and performance documentation matter. All products are manufactured under ISO 13485–compliant processes to align with diagnostic-quality expectations.

Whether you’re optimizing a DETECTR-style Cas12 workflow, building an amplification-free detection format, or locking down reliable supply for a clinical program, TriAltus supports both custom and recurring needs. We also offer custom formulations on request (e.g., glycerol-free) to match downstream requirements and stability targets.

Have a diagnostic enzyme development need? Reach out to TriAltus to discuss specifications, QC requirements, and custom formulation options.